-+ 0.00%
-+ 0.00%
-+ 0.00%

Collegium Pharmaceutical Q3 net income falls 31% to $21.76 million

PUBT·11/05/2026 12:44:42
Listen to the news
Collegium Pharmaceutical Q3 net income falls 31% to $21.76 million
  • Collegium Pharmaceutical’s third-quarter 2026 GAAP net income fell 31% year-over-year to $21.8 million.
  • Quarterly net revenues rose to $216.3 million.
  • JORNAY PM net revenues climbed 24% year-over-year to $51.9 million, while pain portfolio net revenues dropped 18% to $138 million.
  • The $50 million accelerated share repurchase program is expected to settle in the fourth quarter of 2026.
  • Full-year 2026 net revenues guidance was reaffirmed at $825 million to $855 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Collegium Pharmaceutical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050730PRIMZONEFULLFEED9870726) on November 05, 2026, and is solely responsible for the information contained therein.